NCIt related terms : Bendamustine and Rituximab (BR); Bendamustine and Rituximab-rite (BR); Bendamustine and Rituximab-abbs (BR); Bendamustine and Rituximab-pvvr (BR); Bendamustine and Rituximab-arrx (BR); Bendamustine and Rituximab-rixi (BR); Bendamustine and Rituximab-rixa (BR); Bendamustine and Rituximab-blit (BR);
NCIt definition : A regimen consisting of bendamustine and rituximab that can be used for the treatment
of non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL) and small
lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma,
mantle cell lymphoma, Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma,
gastric and nongastric mucosa-associated lymphoid tissue (MALT) lymphoma, and nodal
and splenic marginal zone lymphoma, and nodular lymphocyte-predominant Hodgkin lymphoma
(NLPHL).;
False automatic mappings